Mouse anti-p16INK4a, Clone JC2, CE/IVD certified
p16INK4a, also known as cyclin-dependent kinase inhibitor 2A, is encoded by the CDKN2A gene. It acts as tumor suppressor and decelerates the progression of cells G1 phase to S phase of the cell cycle by inhibiting cyclin dependent kinases 4 and 6 (CDK4 and CDK6), preventing phosphorylation of the retinoblastoma protein (Rb), and thereby hindering the liberation of the transcription factor E2F, which promotes the transcription of target genes that are essential for DNA synthesis.
Mutations as well as changes in the methylation status can alter the expression of the CDKN2A gene resulting in reduced activity or even complete loss of function of the tumor suppressor p16INK4a. Alterations like this often occur as early events during the pathogenesis of solid tumors and are associated with increased risk of a wide range of cancers like melanoma or pancreatic, gastric, esophageal, lung, cervical, laryngeal and oropharyngeal cancers.
The anti- p16INK4a clone JC2 has been extensively tested in our Quality Assurance Laboratories as well as in independent Pathology Laboratories using different manual and automated methods and protocols. The results are extremely convincing, reliable and reproducible.
The antibody is designed for the specific localisation of the protein p16INK4a in formalin-fixed, paraffin-embedded tissue sections. The anti-p16INK4a antibody is intended for in vitro diagnostic use.
p16INK4a detection on cervical intraepithelial neoplasia CIN3 (Mouse anti-p16INK4a, Clone JC2, MSK123-05, 1:50; EDTA pH 9,0; ZytoChem Plus (HRP) Polymer Kit, POLHRP-100; DAB High Contrast, DAB5000PLUS).
Sherr CJ et al. Cold Spring Harb Symp Quant Biol 59:11-19, 1994
Rocco JW & Sidransky D. Experimental Cell Research 264:42-55, 2001
Kotake Y et al. Anticancer Res 35:4397-4401, 2015